Is TMS Therapy Safe? What Research Says About Risks and Results
If you’ve searched for information about TMS therapy, you have likely come across a mix of glowing testimonials and alarming personal stories. Claims that TMS “ruined” someone’s life sit next to clinical descriptions of a well-studied, FDA-cleared treatment. That contrast is confusing, and if you are considering TMS for treatment-resistant depression, you deserve a direct, evidence-based answer rather than either extreme.
At Prime Behavioral Health in Southlake, TX, board-certified psychiatrist Dr. Vishal Shah, MD, and our team of four licensed psychiatric mental health nurse practitioners have provided FDA-approved NeuroStar TMS therapy to patients throughout the Dallas-Fort Worth region for over five years. We accept most major insurance plans including Aetna, BlueCross BlueShield PPO, Optum, United Healthcare, and Cigna. Read verified patient reviews on Google. Telemedicine appointments are available for eligible follow-up care. Call 817-778-8884 to schedule a comprehensive evaluation.
This guide walks through exactly what the research shows about TMS safety: the documented side effects, the real (and rare) risk of seizure, why TMS is so often confused with an entirely different treatment, and how to think about the difference between a treatment that didn’t work and a treatment that caused harm.
The Direct Answer: Yes, TMS Therapy Is Safe
NeuroStar TMS therapy has been FDA-cleared since 2008 and has been used in more than 4 million treatments over the past 17 years. It does not require anesthesia, does not circulate through the bloodstream, and carries no documented risk of memory loss or long-term cognitive impairment. The National Institute of Mental Health (NIMH) recognizes TMS as an established, evidence-based treatment for depression.
That said, “safe” does not mean “without any side effects” or “guaranteed to work.” A responsible answer to this question requires walking through both what the research documents as real risks and why online accounts of TMS are sometimes far more alarming than the clinical data supports.
What FDA Clearance for TMS Actually Required
FDA clearance is not a marketing designation. It requires clinical trial data demonstrating both safety and effectiveness for a specific, defined use. NeuroStar TMS received its original clearance for adults with major depressive disorder in 2008, based on trial data that established its side effect profile and response rates. In 2019, the FDA granted clearance for adolescents ages 15 and older, based on separate trial data specific to that age group. A further clearance covers TMS as an adjunct treatment for Obsessive Compulsive Disorder in adults. Each of these clearances represents an independent review of safety data by the FDA, not a single blanket approval.
The Most Common TMS Side Effects, Documented Honestly
Real side effects exist, and a trustworthy answer names them directly rather than glossing over them.
Side Effect | How Common | What to Expect |
Scalp discomfort at treatment site | Most common; affects a meaningful minority of patients | Typically strongest in the first few sessions, decreases within about a week |
Headache | Second most common | Usually mild to moderate; manageable with standard over-the-counter pain relief |
Facial muscle twitching during pulses | Common during the session itself | Occurs only while the magnetic pulse is active; stops immediately after |
Lightheadedness | Less common | Usually brief and resolves without intervention |
Seizure | Rare, approximately 0.1% or lower per treatment course | The most serious documented risk; screened for extensively before treatment begins |
Fewer than 5% of patients discontinue TMS therapy because of side effects, according to clinical trial data. Most patients who experience scalp discomfort or headache in the first sessions find that it diminishes noticeably as treatment continues.
The Serious Risk to Understand: Seizure
Seizure is the risk that deserves the most direct discussion, because it is the most serious potential adverse event associated with TMS. Published research places the risk at approximately 0.1% or lower per treatment course, meaning it is rare but not zero. This is precisely why a comprehensive psychiatric evaluation, including a detailed review of personal and family seizure history and any condition that might lower seizure threshold, is completed before any patient begins TMS therapy. Patients with an active, unmanaged seizure disorder require specialist evaluation before treatment can be considered.
This screening process exists specifically to keep this already-low risk as low as possible for each patient, rather than applying a one-size-fits-all approach.
Why TMS Therapy Is So Often Confused with ECT
A significant portion of the fear and negative sentiment associated with TMS online traces back to a simple but consequential confusion: mistaking TMS for Electroconvulsive Therapy (ECT). Both are categorized as brain stimulation therapies, both were developed within psychiatry, and both are sometimes discussed together in general health content, but they are fundamentally different treatments with very different risk profiles.
Feature | TMS Therapy | ECT |
Mechanism | Magnetic pulses stimulate the prefrontal cortex | Electrical current induces a controlled seizure |
Anesthesia required | No | Yes, general anesthesia |
Patient awareness during treatment | Fully awake and alert | Unconscious |
Documented memory effects | None | Temporary memory loss is a known risk |
Return to normal activity | Immediately, patient drives themselves home | Requires recovery time and transportation |
If you have read an account describing memory loss, confusion, or a hospital-based recovery process attributed to “TMS,” it is worth considering whether the person may be describing ECT, or conflating the two treatments. For a full side-by-side comparison, see our guide on brain stimulation therapy: TMS vs ECT and what sets them apart.
”TMS Didn’t Work for Me”: Why Non-Response Isn’t the Same as Harm
Clinical data show that approximately 50% of patients with treatment-resistant depression experience significant improvement with NeuroStar TMS, and roughly one in three achieves full remission. Those are strong numbers for a population that has already tried and not responded to antidepressant medication, but they also mean a real portion of patients do not reach these outcomes within a single treatment course.
This is an important distinction to sit with: a treatment not producing the hoped-for result is a genuinely disappointing outcome, and that disappointment is valid. It is not, however, the same thing as the treatment causing injury or harm. Every FDA-approved depression treatment, including every antidepressant medication, has patients who do not respond adequately. Evaluating TMS safety means asking whether the treatment itself causes damage, and the research answer to that specific question remains reassuring even when the effectiveness answer varies by individual.
Who Should Not Receive TMS Therapy
TMS is not appropriate for everyone, and a responsible safety discussion includes clear contraindications:
- Non-removable metal or magnetic-sensitive implants in or near the head, including cochlear implants, aneurysm clips or coils, or certain types of shrapnel
- Implanted cardiac devices such as pacemakers or defibrillators, which require careful evaluation before treatment
- An active, unmanaged seizure disorder, which requires specialist assessment of risks and benefits before proceeding
- Certain neurological conditions that a comprehensive evaluation is designed to identify
Standard dental fillings, dental implants, and most tattoos do not prevent a patient from receiving TMS. A thorough psychiatric evaluation reviews your complete medical history to determine candidacy before any treatment begins.
How TMS Safety Compares to Antidepressant Medication
Context matters when evaluating any treatment’s risk. Antidepressant medications work systemically, meaning they travel through the bloodstream and affect the entire body, which is why they carry documented risks including weight changes, sexual dysfunction, gastrointestinal effects, and discontinuation symptoms when stopped abruptly. Antidepressants also carry an FDA boxed warning regarding increased suicidal thoughts in patients under 25 during the early weeks of treatment.
TMS does not enter the bloodstream and has none of these systemic effects. This does not make TMS risk-free, as this guide has detailed, but it does mean the nature of its risks is different, generally more localized (scalp, head) and less systemic than medication. Understanding the difference between medication and TMS therapy in more detail can help clarify which factors matter most for your specific situation.
What 17 Years of Clinical Use Shows
TMS is not a new or experimental technology. It has been in continuous clinical use since 2008, giving researchers, the FDA, and treating psychiatrists 17 years of post-market safety monitoring to draw on. Over that period and across more than 4 million NeuroStar treatments delivered, no evidence of delayed-onset harm or cumulative long-term risk has emerged. This track record is part of why NeuroStar TMS therapy continues to be recommended by psychiatrists for patients who have not found adequate relief through medication alone.
How Prime Behavioral Health Approaches TMS Safety
Every patient considering TMS therapy at Prime Behavioral Health completes a comprehensive psychiatric evaluation before treatment begins. This evaluation reviews your full medical and mental health history, current medications, any implants or devices in or near your head, and personal or family seizure history. Throughout the treatment course, our team monitors your symptoms and side effects at regular check-ins, so any concerns are addressed promptly rather than discovered after the fact. Learn more about how NeuroStar TMS works and what the full treatment process involves.
Considering TMS Therapy in Southlake and the DFW Area
For patients throughout Southlake, Grapevine, Colleyville, Keller, and the greater Dallas-Fort Worth region who are weighing TMS against continued medication trials, an accurate understanding of the actual risk profile, not the most dramatic story that appears in a search result, is the right foundation for that decision. A comprehensive psychiatric evaluation is the most reliable way to determine whether TMS is an appropriate and safe option for your specific history.
Frequently Asked Questions About TMS Therapy Safety
Is TMS therapy actually safe?
Yes. NeuroStar TMS therapy is FDA-cleared and has been used clinically since 2008, with more than 4 million treatments delivered. Clinical trials and 17 years of real-world use show a well-established safety profile. The most common side effect is mild scalp discomfort during initial sessions, which typically decreases within the first week. TMS does not require anesthesia, does not enter the bloodstream, and carries no documented risk of memory loss or cognitive impairment.
What are the most common side effects of TMS therapy?
The most frequently reported side effect is mild to moderate scalp discomfort or tenderness at the treatment site, which affects a meaningful minority of patients during the first few sessions and typically fades as the brain and scalp adjust. Headache is the second most common side effect, usually mild and manageable with standard over-the-counter pain relief. Some patients notice brief facial muscle twitching during the magnetic pulses, which stops as soon as the session ends. Lightheadedness is reported less frequently. Fewer than 5% of patients discontinue treatment due to side effects.
Can TMS therapy cause seizures?
Seizure is the most serious potential risk associated with TMS therapy, but it is rare. Published research places the seizure risk at approximately 0.1% or lower per treatment course, meaning roughly 1 in 1,000 patients or fewer. This is why every psychiatric evaluation before starting TMS includes careful screening for seizure history, family history of seizure disorders, and any condition that might lower seizure threshold. Patients with an active, unmanaged seizure disorder are generally not candidates for TMS without further specialist evaluation.
Is TMS the same as ECT (electroconvulsive therapy)?
No, and this is one of the most common sources of confusion and fear around TMS. Electroconvulsive Therapy (ECT) delivers electrical current directly through the brain to intentionally induce a controlled seizure, requires general anesthesia, and carries a real risk of short-term memory loss. TMS uses magnetic pulses, not electrical current, does not induce a seizure as part of its mechanism, requires no anesthesia, and has no documented association with memory loss. Patients remain fully awake and alert throughout a TMS session and drive themselves home afterward. Many negative perceptions of TMS online actually stem from confusion with ECT rather than TMS itself.
Why do some people say TMS therapy “ruined their life” or didn’t work?
When researching TMS, it is common to encounter strongly negative personal accounts online. In our clinical experience, and consistent with published response data, these accounts most often reflect one of a few situations: the person did not achieve the level of symptom improvement they had hoped for (a real and disappointing outcome, but different from the treatment causing harm), the person is describing an ECT experience while using the term “TMS” interchangeably, or the person experienced a temporary and expected side effect such as headache or scalp discomfort that was more intense than anticipated. It is important to distinguish between TMS not producing the desired result and TMS causing injury. These are two very different outcomes, and the safety data on the second is reassuring even when the first is disappointing.
Does TMS therapy cause memory loss or cognitive problems?
No. This is one of the clearest distinctions between TMS and ECT. Clinical trials involving thousands of patients and over a decade of post-market safety monitoring have found no evidence that TMS causes memory loss, cognitive decline, or impaired concentration. Because TMS does not induce a seizure and does not require anesthesia, it avoids the specific mechanisms that produce memory-related side effects in ECT. Some patients report improved concentration as their depression symptoms improve during treatment.
Who should not receive TMS therapy?
TMS therapy is not appropriate for patients with certain non-removable metal or magnetic-sensitive implants in or near the head, including cochlear implants, aneurysm clips or coils, or certain types of shrapnel. Patients with implanted cardiac devices such as pacemakers or defibrillators require careful evaluation before treatment. Patients with an active, unmanaged seizure disorder require specialist assessment of the risks and benefits before proceeding. A comprehensive psychiatric evaluation, including a review of implants, devices, and neurological history, is completed before any patient begins TMS therapy.
Is TMS therapy FDA-approved?
Yes. The FDA cleared NeuroStar TMS therapy for major depressive disorder in adults in 2008. In 2019, NeuroStar received FDA clearance for adolescents ages 15 and older, becoming the first TMS system approved for this age group. NeuroStar also holds FDA clearance as an adjunct treatment for Obsessive Compulsive Disorder in adults. Each clearance was based on clinical trial data demonstrating both safety and effectiveness for the approved use.
What does the long-term research say about TMS safety?
TMS has been in clinical use since 2008, giving researchers and clinicians 17 years of post-market safety data. No evidence of delayed-onset harm, cumulative risk, or long-term adverse effects has emerged during this period. NeuroStar specifically has been used in more than 4 million treatments. The National Institute of Mental Health recognizes TMS as an established evidence-based treatment for depression, and ongoing research continues to monitor safety and effectiveness across diverse patient populations.
Can TMS therapy make depression worse?
TMS therapy is not associated with worsening depression as a direct effect of the treatment itself. As with any depression treatment, including antidepressant medications, individual response varies, and a small number of patients do not experience improvement during a treatment course. Your psychiatrist monitors your symptoms throughout treatment using standardized assessments specifically to identify early if a different approach is needed. If you experience worsening mood during TMS, this should be reported to your provider immediately so your treatment plan can be reassessed.
What happens if TMS therapy doesn’t work for me?
Approximately 50% of patients with treatment-resistant depression experience significant improvement with TMS, and about one in three achieves full remission. This means a meaningful portion of patients do not reach these outcomes within a single treatment course, which is an honest and important statistic to understand before starting. If TMS does not produce adequate improvement, your psychiatrist will discuss alternative or additional options, which may include adjusting the TMS protocol, combining TMS with medication, or exploring other treatment approaches. Non-response is a treatment outcome to plan around, not a safety failure.
How does TMS therapy’s safety profile compare to antidepressant medication?
Antidepressant medications work systemically, traveling through the bloodstream and affecting the entire body, which is why they carry risks such as weight changes, sexual dysfunction, gastrointestinal effects, and discontinuation symptoms. TMS does not enter the bloodstream and has no documented systemic side effects. Antidepressants also carry an FDA boxed warning regarding increased suicidal thoughts in patients under 25 during initial treatment, a risk that does not apply to TMS. Both treatments are considered safe when properly prescribed and monitored, but their risk profiles are meaningfully different.
Is TMS therapy safe for teenagers?
Yes. NeuroStar TMS received FDA clearance for patients ages 15 and older based on clinical trial data demonstrating a safety and side effect profile in adolescents comparable to adults. The most common side effect in teenagers, as in adults, is mild scalp discomfort during initial sessions. Adolescent TMS treatment requires parental consent and involvement throughout the evaluation and treatment process.
What screening happens before starting TMS therapy to ensure safety?
Before beginning TMS therapy, a comprehensive psychiatric evaluation reviews your full medical and mental health history, current medications, any metal implants or devices in or near your head, personal or family history of seizures, and any neurological conditions. This screening identifies whether TMS is an appropriate and safe treatment option for your specific situation before any treatment begins. Ongoing monitoring throughout the treatment course allows your provider to identify and address any concerns promptly.
How do I know if TMS therapy is worth trying for my depression?
TMS is generally worth considering for patients who have tried at least one antidepressant medication without adequate relief, who want to avoid the systemic side effects associated with medication, or who have not found sufficient benefit from psychotherapy alone. Given its well-documented safety profile and the significant improvement rates seen in treatment-resistant depression, TMS represents a low-risk option relative to its potential benefit for appropriate candidates. A comprehensive psychiatric evaluation is the best way to determine whether your specific symptoms and history make you a good candidate.
Make an Informed Decision About TMS Therapy
TMS therapy has a well-documented safety profile supported by 17 years of clinical use and millions of treatments. Real, if generally mild, side effects exist and deserve honest discussion. The rare seizure risk is real and is precisely why careful screening happens before every treatment course. And much of the most alarming content about TMS online reflects confusion with ECT or the genuine disappointment of non-response rather than evidence of harm.
Key takeaways from this guide:
- TMS is FDA-cleared, has no documented memory or cognitive side effects, and does not require anesthesia
- The most common side effects are scalp discomfort and headache, both typically mild and diminishing over the first week
- Seizure risk is rare, approximately 0.1% or lower per treatment course, and is specifically screened for beforehand
- TMS and ECT are different treatments with different risk profiles; confusing the two is a major source of online fear
If you are in Southlake, Grapevine, Keller, Fort Worth, or anywhere in the greater DFW area and want an honest, evaluation-based answer about whether TMS therapy is right and safe for you, Prime Behavioral Health is here to help. Our board-certified psychiatrist Dr. Vishal Shah, MD, and licensed psychiatric team have extensive experience screening for and safely administering NeuroStar TMS therapy. We accept Aetna, BlueCross BlueShield PPO, Optum, United Healthcare, and Cigna. Read our patient reviews on Google, then schedule your comprehensive evaluation online or call Prime Behavioral Health at 817-778-8884. The right answer for your situation starts with an accurate evaluation, not an anonymous review.